Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic
Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Purpose
Assess short-term real-world outcomes in neovascular aged-related macular degeneration (nAMD) treated with novel faricimab.
Methods
Retrospective case series of nine patients with nAMD (11 eyes) treated with faricimab between May and November 2022. Treatment-naïve patients and non-naïve patients underwent logMAR best corrected visu...
Alternative Titles
Full title
Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10564726
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10564726
Other Identifiers
ISSN
0950-222X,1476-5454
E-ISSN
1476-5454
DOI
10.1038/s41433-023-02505-z
